OncoMatch/Clinical Trials/NCT06472739
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
Is NCT06472739 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies GM-CSF for gm-csf.
Treatment: GM-CSF — To evaluate the efficacy of GM-CSF to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage II, III, IVA
Excluded: Stage I, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Exception: except for non-melanomatous skin cancers outside intended RT treatment volume
History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)
Cannot have received: chemotherapy
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Cannot have received: surgery
Exception: except diagnostic
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Lab requirements
Blood counts
wbc≥4×109/l, plt≥100×109/l, hgb≥90g/l
Kidney function
creatinine clearance rate≥60 ml/min or creatinine< 1.5×uln
Liver function
alt, ast <1.5×uln concomitant with alp ≤2.5×uln, and bilirubin ≤uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06472739 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III or IVA is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify